Also known as: respiratory syncytial virus (RSV)
Real-world studies show nirsevimab reduced RSV infant hospitalizations by up to 72% and maternal vaccination cut hospitalizations by nearly 70%, with benefits extending into the second RSV season.
A French cohort study found nirsevimab at birth reduces RSV-related hospitalizations in infants by 22% compared to maternal vaccination. UK data shows the maternal RSV vaccine provides over 80% protection when given at least four weeks before birth. Both strategies aim to protect vulnerable infants during their first months of life.
Merck's Enflonsia (clesrovimab) receives EU approval for RSV prevention in infants. Separately, researchers identify a monoclonal antibody cocktail from pediatricians' immune cells that shows potent protection against RSV and hMPV in animal studies.
Enanta Pharmaceuticals will present Phase 2b data showing zelicapavir improves RSV symptom resolution by about a week and reduces hospitalization rates. The oral N-protein inhibitor also demonstrates high resistance barrier in pediatric studies. Presentations will occur at the ESCMID Global 2026 conference in Munich.
The FDA has expanded approval of GSK's Arexvy RSV vaccine to include adults aged 18 to 49 years at increased risk for lower respiratory tract disease, based on phase 3b trial data showing noninferior immune response.
GSK's RSV vaccine Arexvy received expanded FDA approval to cover all high-risk adults, adding approximately 21 million Americans under 50 to the eligible population and matching competitor approvals from Pfizer and Moderna.
Researchers have created a nasal vaccine platform that protects mice against flu, COVID-19, SARS, and bacterial infections by activating both innate and adaptive immune systems, offering a fundamentally different approach to disease prevention.
New real-world effectiveness data presented at RSVVW'26 demonstrate that GSK's Arexvy RSV vaccine was associated with a 75.6% reduction in RSV-related hospitalizations among adults aged 60 and older, with exploratory findings suggesting potential benefits for cardiovascular and respiratory complications.
The American Medical Association and University of Minnesota's Vaccine Integrity Project are creating an independent vaccine review system after major changes at the CDC raised concerns among public health experts.
The FDA agreed to review Moderna's mRNA flu vaccine application after initially rejecting it, reversing course within a week. The agency will now consider full approval for adults 50-64 and accelerated approval for those 65 and above, with a decision expected by August 5.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07289542 |
Phase II Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 50 Years or Above |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT07289503 |
Phase I Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 18 Years or Above |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT07200206 |
A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea |
RECRUITING | |
| NCT07122661 |
STudy of Real World vaccinE Effectiveness of maTernal RSVpreF vaccinatiON Against Respiratory Syncytial Virus (RSV) in Hospitalised Infants in Australia (STREETON) |
ACTIVE_NOT_RECRUITING | |
| NCT07117487 |
A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age |
COMPLETED | PHASE3 |
| NCT06754605 |
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine |
RECRUITING | PHASE1/PHASE2 |
| NCT06647654 |
Impact and Effectiveness of ABRYSVO® Vaccination During Pregnancy |
ACTIVE_NOT_RECRUITING | |
| NCT06593587 |
A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea |
COMPLETED | PHASE3 |
| NCT06488300 |
Assessing Antiviral Treatments in Early Symptomatic RSV |
RECRUITING | PHASE2 |
| NCT06325657 |
A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants |
COMPLETED | PHASE3 |
